- Home
- OLMA vs ZVRA Comparison
OLMA vs ZVRA Comparison
Compare OLMA & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLMA | ZVRA |
|---|---|---|
| Founded | 2006 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 863.0M | 741.9M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | OLMA | ZVRA |
|---|---|---|
| Price | $9.37 | $12.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 5 |
| Target Price | ★ $44.89 | $23.00 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 15.00 | ★ 159.21 |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | ★ N/A | $21.62 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $4.02 | $7.16 |
| 52 Week High | $36.26 | $14.27 |
Technical Indicators
Market Signals| Indicator | OLMA | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 28.60 | 61.82 |
| Support Level | $7.79 | $8.26 |
| Resistance Level | $9.54 | $14.27 |
| Average True Range (ATR) | 0.77 | 0.76 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 10.83 | 65.01 |
Price Performance
Historical ComparisonAbout OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.